

Sigurd Broesby-Olsen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3141771/sigurd-broesby-olsen-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

46
papers

1,708
citations

19
h-index

41
g-index

50
ext. papers

2,105
ext. citations

5.4
avg, IF

4.28
L-index

#	Paper	IF	Citations
46	Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group.. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022 ,	5.4	5
45	Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal.. <i>HemaSphere</i> , 2021 , 5, e646	0.3	16
44	Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021 , 9, 3918-3928	5.4	8
43	COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM). <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021 , 9, 2139-2144	5.4	17
42	Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. <i>International Journal of Laboratory Hematology</i> , 2021 , 43, e19-e25	2.5	2
41	Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosis. <i>American Journal of Human Genetics</i> , 2021 , 108, 284-294	11	6
40	Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions. <i>Journal of Allergy and Clinical Immunology</i> , 2020 , 146, 300-306	11.5	15
39	Definition, aims, and implementation of GA LEN/HAEi Angioedema Centers of Reference and Excellence. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020 , 75, 2115-2123	9.3	10
38	Pioneer Part 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib in Indolent Systemic Mastocytosis. <i>Blood</i> , 2020 , 136, 41-42	2.2	3
37	Mastocytosis: Overview of Diagnosis and Classification 2020 , 23-34		
36	Clinical validation of a new commercial highly sensitive KIT D816V mutation analysis in mastocytosis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020 , 75, 1489-1491	9.3	4
35	It looks like childhood eczema but is it?. <i>Clinical and Experimental Allergy</i> , 2019 , 49, 744-753	4.1	6
34	Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019 , 7, 1125-1133.e1	5.4	106
33	Towards rational diagnostics in mastocytosis: clinical validation of sensitive KIT D816V mutation analysis of unfractionated whole-blood. <i>Leukemia and Lymphoma</i> , 2019 , 60, 268-270	1.9	2
32	Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome. <i>International Archives of Allergy and Immunology</i> , 2019 , 180, 44-51	3.7	46
31	Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy. <i>Blood</i> , 2019 , 134, 2950-2950	2.2	2
30	Adherence to adrenaline autoinjector prescriptions in patients with anaphylaxis. <i>Clinical and Translational Allergy</i> , 2019 , 9, 59	5.2	4

29	Exercise-induced anaphylaxis: causes, consequences, and management recommendations. <i>Expert Review of Clinical Immunology</i> , 2019 , 15, 265-273	5.1	16
28	Atopic diseases and type I sensitization from adolescence to adulthood in an unselected population (TOACS) with focus on predictors for allergic rhinitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019 , 74, 308-317	9.3	10
27	Everyday life and mastocytosis from a patient perspective-a qualitative study. <i>Journal of Clinical Nursing</i> , 2019 , 28, 1114-1124	3.2	7
26	Venom anaphylaxis can mimic other serious conditions and disclose important underlying disease. <i>Annals of Allergy, Asthma and Immunology</i> , 2018 , 120, 338-339	3.2	1
25	Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018 , 73, 230-238	9.3	59
24	Pediatric Expression of Mast Cell Activation Disorders. <i>Immunology and Allergy Clinics of North America</i> , 2018 , 38, 365-377	3.3	8
23	Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2018 , 178, 509-519	4	173
22	Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. <i>Cancer Research</i> , 2017 , 77, 1261-1270	10.1	162
21	Prospective evaluation of the diagnostic value of sensitive KIT D816V mutation analysis of blood in adults with suspected systemic mastocytosis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017 , 72, 1737-1743	9.3	24
20	Patterns of anaphylaxis after diagnostic workup: A follow-up study of 226 patients with suspected anaphylaxis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017 , 72, 1944-1952	9.3	25
19	Comparison of gDNA-based versus mRNA-based KIT D816V mutation analysis reveals large differences between blood and bone marrow in systemic mastocytosis. <i>British Journal of Haematology</i> , 2017 , 178, 330-332	4.5	5
18	Risk of solid cancer, cardiovascular disease, anaphylaxis, osteoporosis and fractures in patients with systemic mastocytosis: A nationwide population-based study. <i>American Journal of Hematology</i> , 2016 , 91, 1069-1075	7.1	40
17	Targeted ultradeep next-generation sequencing as a method for KIT D816V mutation analysis in mastocytosis. <i>European Journal of Haematology</i> , 2016 , 96, 381-8	3.8	8
16	Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. <i>Journal of Allergy and Clinical Immunology</i> , 2016 , 137, 35-45	11.5	209
15	Multidisciplinary Management of Mastocytosis: Nordic Expert Group Consensus. <i>Acta Dermato-Venereologica</i> , 2016 , 96, 602-12	2.2	11
14	Platelet-activating factor decreases skin keratinocyte tight junction barrier integrity. <i>Journal of Allergy and Clinical Immunology</i> , 2016 , 138, 1725-1728.e3	11.5	4
13	A child with mastocytosis and lymphomatoid papulosis. <i>Clinical Case Reports (discontinued)</i> , 2016 , 4, 517-9.7		3
12	KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. <i>Leukemia</i> , 2015 , 29, 1223-32	10.7	164

11	Recognizing mastocytosis in patients with anaphylaxis: value of KIT D816V mutation analysis of peripheral blood. <i>Journal of Allergy and Clinical Immunology</i> , 2015 , 135, 262-4	11.5	44
10	Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis. <i>American Journal of Hematology</i> , 2014 , 89, 493-8	7.1	72
9	Treatment strategies in mastocytosis. <i>Immunology and Allergy Clinics of North America</i> , 2014 , 34, 433-47	3.3	43
8	Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014 , 69, 1267-74	9.3	119
7	Epidemiology of systemic mastocytosis in Denmark. <i>British Journal of Haematology</i> , 2014 , 166, 521-8	4.5	104
6	Anaphylaxis caused by mosquito allergy in systemic mastocytosis. <i>Lancet, The</i> , 2013 , 382, 1380	4.0	31
5	KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , 2013 , 132, 723-728	11.5	36
4	KIT D816V mutation-positive cell fractions in lesional skin biopsies from adults with systemic mastocytosis. <i>Dermatology</i> , 2013 , 226, 233-7	4.4	8
3	Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis. <i>European Journal of Haematology</i> , 2012 , 89, 42-6	3.8	38
2	Adult-onset systemic mastocytosis in monozygotic twins with KIT D816V and JAK2 V617F mutations. <i>Journal of Allergy and Clinical Immunology</i> , 2012 , 130, 806-8	11.5	22
1	Multiple self-healing squamous epithelioma of Ferguson-Smith: observations in a Danish family covering four generations. <i>Acta Dermato-Venereologica</i> , 2008 , 88, 52-6	2.2	9